Latest Recruitment News

ASX Limited delivered a robust first half in 2025 with record operating revenue and a 10% rise in underlying NPAT, underscoring its strategic focus on technology modernisation and disciplined cost management.

Nanoveu Limited has completed the strategic acquisition of Embedded A.I. Systems Pte. Ltd. (EMASS), positioning itself at the forefront of ultra-low-power AI-driven edge semiconductor solutions. This move aims to enhance its EyeFly3D™ platform and expand into rapidly growing markets such as wearables, IoT, and autonomous devices.

BlinkLab has secured North Shore Pediatric Therapy as the second US clinical site in its autism diagnostic study, enhancing recruitment and data quality with a leading Chicago-based specialist.

Radiopharm Theranostics' RAD 101 radiotracer demonstrates high sensitivity in detecting brain metastases using a novel PET-mpMRI approach, with a Phase 2b trial now recruiting in the US.

Nyrada has secured ethics approval to begin its first-in-human Phase Ia trial of NYR-BI03, a promising neuro- and cardioprotective drug candidate. Recruitment starts soon, with dosing expected by March and results due in Q3 2025.

Opyl Limited has entered a strategic partnership with Avion, integrating its AI-powered TrialKey platform to enhance clinical trial design and execution across the APAC region.

Vitrafy Life Sciences reports strong progress in cryopreservation technology development and US market expansion following a successful $35 million IPO. The company highlights improved biological sample preservation outcomes and strategic commercial milestones.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.

Polymetals Resources reports solid progress in restarting its Endeavor Silver Zinc Mine, with key hires completed and mining activities underway, aiming for cash flow in the first half of 2025.

Larvotto Resources has reported robust progress at its Hillgrove Antimony-Gold Project, highlighted by exceptional drilling results and a successful $30 million capital raise, positioning the company for production by late 2025.

Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.

Oakridge International Limited reports a strong quarterly performance driven by increased contracted orders, strategic partnerships, and technological innovation, positioning the company for sustained growth into 2025.